STOCK TITAN

TREVENA INC - TRVN STOCK NEWS

Welcome to our dedicated page for TREVENA news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on TREVENA stock.

Trevena, Inc. (Nasdaq: TRVN) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting G protein-coupled receptors (GPCRs). The company's mission is to improve patient outcomes and reduce healthcare costs through novel therapies. Trevena's pipeline includes four key drug candidates:

  • TRV130 (OLINVYK®): An FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing. Recently, OLINVYK's effectiveness was assessed in the VOLITION study, showing promising results in terms of respiratory, gastrointestinal, and cognitive function outcomes in postoperative settings.
  • TRV027: Evaluated in a Phase 2b study for treating acute heart failure, this candidate aims to address unmet needs in cardiovascular treatment.
  • TRV734: Completed Phase 1 testing for the oral treatment of acute and chronic pain, TRV734 seeks to provide a non-opioid alternative for pain management.
  • TRV250: In preclinical development for migraine treatment, focusing on innovative solutions for CNS disorders.

Trevena's pipeline is based on Nobel Prize-winning research, emphasizing its commitment to pioneering medical advancements. The company has collaborations with prominent institutions like Wake Forest Baptist Health and the Cleveland Clinic, ensuring rigorous evaluation and development of its therapies. Trevena is also exploring TRV045 for diabetic neuropathic pain and epilepsy, showcasing the potential impact beyond pain management.

Financially, Trevena has shown resilience, recently reporting a net loss reduction and strengthening its balance sheet with significant capital injections. The company continues to focus on strategic partnerships and innovative research to maintain its competitive edge in the biopharmaceutical industry.

For more information, please visit www.Trevena.com.

Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) announced that Wake Forest Baptist Health Medical Center will participate in the VOLITION study to assess the impact of OLINVYK (oliceridine) on postoperative respiratory, gastrointestinal, and cognitive outcomes. The study, led by Cleveland Clinic, will enroll approximately 200 adults and is expected to begin patient enrollment in Q3 2021. Mark A. Demitrack, M.D., stated that the results could enhance understanding of OLINVYK's clinical value, aiming to address significant clinical needs related to pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
Rhea-AI Summary

Trevena, Inc. (TRVN) reported a net loss of $14 million for Q2 2021, up from $6.2 million the previous year. The company has achieved 35 formulary approvals for OLINVYK, with a goal of 100 by year-end. Ongoing studies for OLINVYK and TRV027 aim to enhance understanding of their efficacy in various medical conditions. Cash reserves stand at $91 million, sufficient to cover operational expenses through Q4 2022. Trevena's stock has been added to Russell 2000, Russell 3000, and Russell Microcap indexes, enhancing its visibility among investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
none
-
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) announced an exploratory analysis revealing that patients treated with OLINVYK (oliceridine) are approximately 50% less likely to experience adverse events compared to those treated with IV morphine at equal analgesic levels. Conducted using data from the OLINVYK Phase 3 program, the analysis showed a significant odds ratio indicating lower treatment-emergent adverse events for OLINVYK, suggesting a favorable benefit-risk profile for post-operative pain management. The publication can be found in the relevant medical journal and was authored by Dr. Gregory B. Hammer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) will announce its second quarter financial results on August 12, 2021, before the market opens. A conference call will follow at 8:00 a.m. ET, featuring key executives including President Carrie Bourdow and CFO Barry Shin. Trevena focuses on developing novel medicines for central nervous system disorders, with one approved product, OLINVYK® (oliceridine) injection, and a pipeline including four investigational drug candidates targeting migraine and opioid use disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) has initiated patient enrollment for the ACTIV-4 Host Tissue trial, focusing on COVID-19 treatments. TRV027, an innovative AT1 receptor selective agonist, aims to combat the damaging effects of COVID-19 on the lungs and blood clotting. The trial will include around 1,600 patients at over 50 sites across the U.S. TRV027 has previously shown promise in clinical settings with a favorable safety profile. The study's goal is to evaluate the effectiveness of various agents, including TRV027, in preventing severe outcomes in hospitalized COVID-19 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
covid-19
-
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) announced a published health economic model for its drug OLINVYK (oliceridine) in the Journal of Comparative Effectiveness Research. The model shows significant cost savings for hospitals using OLINVYK over IV morphine for postoperative pain management. The analysis indicates a reduction in total care costs per 1,000 patients due to fewer adverse effects noted in Phase 3 trials. This publication is expected to aid formulary reviews, supporting the drug's utilization in acute pain management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Rhea-AI Summary

Trevena, Inc. (TRVN) has partnered with Nhwa to begin a Phase 3 trial for OLINVYK (oliceridine) injection in China, targeting acute pain management. The trial, which has enrolled its first patient, aims to include around 160 participants following abdominal surgery. Trevena expects to gain 10% royalty on net sales and anticipates receiving approval and commercialization milestones. The study's primary endpoint focuses on pain relief efficacy, with safety assessed via various adverse events. Successful completion may lead to regulatory filing for OLINVYK in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership clinical trial
-
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) has announced a new study evaluating the respiratory effects of OLINVYK in elderly and obese patients. The Phase 1 trial, led by Dr. Albert Dahan, will compare OLINVYK with IV morphine using an innovative clinical utility function analysis. Enrollment is expected in Q3 2021, aiming for topline data by YE 2021. This study is part of Trevena’s strategy to enhance evidence for OLINVYK’s clinical profile and assess its therapeutic potential in managing acute pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) announced its addition to the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes, effective June 28, 2021. This inclusion signifies a positive recognition for Trevena, reflecting the value from the launch of its product OLINVYK and progress in its pipeline. The move is expected to enhance the company's visibility, broaden its shareholder base, and improve stock liquidity, according to President and CEO Carrie Bourdow. Russell indexes manage approximately $9 trillion in assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.16%
Tags
none
Rhea-AI Summary

Trevena, Inc. (Nasdaq: TRVN) announced that the National Institute on Drug Abuse (NIDA) has resumed patient recruitment for the proof-of-concept study of TRV734, a novel oral treatment for opioid use disorder (OUD). The study, paused in March 2020 due to COVID-19, aims to evaluate TRV734's efficacy in reducing withdrawal symptoms. The clinical trial will involve approximately 50 patients and assess both safety and tolerability. TRV734 targets the mu-opioid receptor and shows promise in preclinical studies, potentially offering a better-tolerated option than existing treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none

FAQ

What is the current stock price of TREVENA (TRVN)?

The current stock price of TREVENA (TRVN) is $1.76 as of December 20, 2024.

What is the market cap of TREVENA (TRVN)?

The market cap of TREVENA (TRVN) is approximately 1.3M.

What is Trevena, Inc.?

Trevena, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting GPCRs to improve patient outcomes and reduce healthcare costs.

What is OLINVYK®?

OLINVYK® (TRV130) is an FDA-designated breakthrough therapy for the intravenous treatment of acute moderate to severe pain, currently in Phase 3 testing.

What recent developments has Trevena announced?

Trevena recently reported promising results from the VOLITION study, assessing OLINVYK’s impact on respiratory, gastrointestinal, and cognitive functions in postoperative settings. They also received capital injections to strengthen their financial position.

What is TRV045?

TRV045 is an investigational drug for diabetic neuropathic pain and epilepsy, showing a favorable safety and tolerability profile in recent studies.

How is Trevena's financial performance?

Trevena has shown improved financial performance by reducing net loss and securing significant capital injections, positioning itself for future development and growth.

What types of products does Trevena develop?

Trevena focuses on novel therapies for acute and chronic pain, migraine treatment, heart failure, and CNS disorders, leveraging cutting-edge research and strategic collaborations.

Are Trevena's products FDA approved?

OLINVYK® is FDA-designated as a breakthrough therapy for acute pain, while other candidates like TRV045, TRV250, and TRV734 are in various stages of clinical and preclinical testing.

What partnerships does Trevena have?

Trevena collaborates with institutions like Wake Forest Baptist Health and the Cleveland Clinic to ensure rigorous evaluation and development of its therapies.

Where can I find more information about Trevena’s research?

More information about Trevena’s research and developments can be found on their official website: www.Trevena.com.

What are the primary focus areas of Trevena's research?

Trevena's primary research areas include treatments for acute and chronic pain, migraine, heart failure, and CNS disorders, based on innovative approaches targeting GPCRs.

TREVENA INC

Nasdaq:TRVN

TRVN Rankings

TRVN Stock Data

1.27M
850.11k
0.38%
14.34%
6.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHESTERBROOK